Mancone S, et al. - In order to assess the prevalence of immune checkpoint inhibitors (ICIs) associated immune-related adverse events (IRAEs), researchers performed a retrospective cohort study of patients treated at their institution with Immune checkpoint inhibitors (ICIs) from 2005 to 2017 and enrolled patients with new neurologic ICD codes documented during or after ICI treatment. The incidence of neurologic IRAEs from ICIs was 0.95% in this clinical practice study. Despite occurring rarely, neurologic IRAEs can be highly variable and severe. More severe IRAEs were observed among patients who received combination immunotherapy. Observations signify the role neurologists in the early identification and management of IRAEs to reduce long-term morbidity and mortality.